FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
ABERDEEN, Scotland and Singapore, 10th December, 2018 – TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the
"treatment of frontotemporal dementia". The term Frontotemporal Dementia (FTD) covers a number of sub-types of dementia, all of which are characterized by a progressive loss of neurons in the frontal and/or temporal lobes of the brain.
Read more here.
FDA grants orphan-drug designation for LMTX
TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for
Recent News
Kath Martin discusses working as the Data Vendor Management Lead at TauRx
Jan 19, 2022
TauRx is sponsoring a focused discussion panel at The Scotsman Life Sciences Conference #ScotLifeSci21, 2nd December, titled Digital Redesign – It’s Win:Win Isn’t It?
Nov 25, 2021
TauRx is proud to be Gold Sponsor and will present at Alzheimer Europe 2021, 29 November – 1 December.
Nov 24, 2021
Roxanna Boyd, discusses working as an Archivist for TauRx and the importance of strong communication skills for the role.
Oct 27, 2021